Ai Di Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 28-07-2024
- Paid Up Capital ₹ 0.10 M
as on 28-07-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 123.20%
(FY 2023)
- Ebitda 363.99%
(FY 2023)
- Net Worth 1.97%
(FY 2023)
- Total Assets 47.52%
(FY 2023)
About Ai Di Pharmaceuticals
The Corporate was formerly known as Asmara India Marketing Private Limited. The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vandana Parikh and Kirit Parikh serve as directors at the Company.
- CIN/LLPIN
U52390DL2015PTC279566
- Company No.
279566
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ai Di Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vandana Parikh  | Director | 11-Mar-2020 | Current |
| Kirit Parikh | Director | 28-Apr-2015 | Current |
Financial Performance of Ai Di Pharmaceuticals.
Ai Di Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 123.2% increase in profit. The company's net worth moved up by a moderate rise of 1.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ai Di Pharmaceuticals?
In 2023, Ai Di Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ai Di Pharmaceuticals?
Unlock and access historical data on people associated with Ai Di Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ai Di Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ai Di Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
